Stejskal V D, Forsbeck M, Nilsson R
Immunotoxicology Section, Safety Assessment, Gärtuna, Sweden.
J Invest Dermatol. 1990 Jun;94(6):798-802. doi: 10.1111/1523-1747.ep12874656.
The lymphocyte transformation test (LTT) has been used for evaluation of in vitro lymphocyte responses in 18 patients with dermatitis and positive patch tests to 200 ppm of a combination of 5-chloro-2-methylisothiazolinone and 28methylisothiazolinone (MCI) in nine patients with dermatitis unrelated to MCI and in seven subjects without skin diseases. Two workers sensitized by occupational exposure to a formulation containing 1,2-benzisothiazolin-3-one (BIT) were also studied. Lymphocytes from nine patch-test-positive patients proliferated vigorously to MCI in vitro. Lymphocytes from the remaining nine patients were not stimulated. Lymphocytes from two BIT-sensitized workers responded to BIT in vitro. The lymphocyte proliferation to isothiazolinones indicates the presence of memory cells in the patients' blood and confirms immunologic reaction to the inducing agent. To establish clinical relevance of LTT results, 12 MCI patch-test-positive patients underwent "use test" with lotion containing 15 ppm MCI. Four of five LTT-positive patients were use-test-positive, whereas seven of seven LTT-negative patients were use-test-negative. LTT-positive and lotion-positive patients responded to 100 ppm or lower concentrations of MCI on patch testing, whereas seven of eight LTT-negative and lotion-negative patients responded to 200 ppm only. In the case of MCI, proliferation was due to the chlorinated component, indicating that this part contains an allergenic epitope. Finally, MCI-specific lymphocyte proliferation was observed only in patients with MCI-positive skin test, but not in nine patients with dermatitis induced by other agents, or in seven subjects without skin diseases. Thus, the lymphocyte transformation test is able to distinguish between irritant and allergic skin responses. It may also be valuable in establishing the clinically relevant patch-test concentration of allergens with irritative properties.
淋巴细胞转化试验(LTT)已用于评估18例皮炎患者以及9例与MCI无关的皮炎患者和7例无皮肤疾病受试者对200 ppm 5-氯-2-甲基异噻唑啉酮和2-甲基异噻唑啉酮(MCI)混合物的体外淋巴细胞反应。还研究了2名因职业接触含1,2-苯并异噻唑啉-3-酮(BIT)制剂而致敏的工人。9例斑贴试验阳性患者的淋巴细胞在体外对MCI有强烈增殖反应。其余9例患者的淋巴细胞未受到刺激。2名BIT致敏工人的淋巴细胞在体外对BIT有反应。淋巴细胞对异噻唑啉酮的增殖表明患者血液中存在记忆细胞,并证实对诱导剂有免疫反应。为确定LTT结果的临床相关性,12例MCI斑贴试验阳性患者用含15 ppm MCI的洗剂进行了“使用试验”。5例LTT阳性患者中有4例使用试验阳性,而7例LTT阴性患者中有7例使用试验阴性。LTT阳性且洗剂阳性的患者在斑贴试验中对100 ppm或更低浓度的MCI有反应,而8例LTT阴性且洗剂阴性的患者中有7例仅对200 ppm有反应。就MCI而言,增殖是由氯化成分引起的,表明该部分含有致敏表位。最后,仅在MCI皮肤试验阳性的患者中观察到MCI特异性淋巴细胞增殖,而在9例由其他因素引起的皮炎患者或7例无皮肤疾病的受试者中未观察到。因此,淋巴细胞转化试验能够区分刺激性和过敏性皮肤反应。它在确定具有刺激性的过敏原的临床相关斑贴试验浓度方面可能也有价值。